The Florida Second District Court of Appeal has renewed a woman’s lawsuit claiming she suffered permanent eye damage when her ophthalmologist misdiagnosed her during nasal surgery. In its opinion, the appellate court ruled that the trial court erred when it dismissed the lawsuit.
Recent reports of retinal atrophy have raised concerns on potential long-term safety.
The advanced swept-source OCT technology allows visualization of the variations in the normal changes and those associated with aging in the posterior vitreous.
The treatment of vision problems can help improve the quality of life for many people in the city.
Fluocinolone acetonide intravitreal implant or faricimab (6.0 mg) injections versus observation will be studied for the prevention of visual acuity loss due to radiation retinopathy
Jeremy Tan, MD, discusses the latest trends in eye trauma surgery at the Dean McGee Eye Institute.
Coherus BioSciences’ ranibizumab-eqrn is the first and only FDA-approved biosimilar interchangeable with ranibizumab injection for all indications, with 12 months of interchangeability exclusivity.
NYU Langone Health has been recognized as No. 1 in quality and safety for inpatient and ambulatory care by Vizient Inc.
Co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, and Oluwatosin U. Smith, MD, of Glaucoma Associates of Texas in Dallas break down the top reasons to attend this year's Ophthalmology Times® EyeCon 2022 in a series of video segments.
Provectus will have an exclusive worldwide license of intellectual property developed by the Ophthalmic Biophysics Center of the Bascom Palmer Eye Institute.
The authors noted that the proportion of patients losing fewer than 15 letters from the baseline BCVA score in the study eye was comparable between the two groups.
The clinical trial is examining the efficacy of two doses of UBX1325 compared to every other month treatment with aflibercept through 24 weeks.
A powerful conversation about expectations can open communication and trust.
According to Nicox SA, the patients made their final 3-month visit last week. Topline results of the trial are expected in November.
Faricimab simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditions.
Elizabeth Yeu, MD, will highlight pearls for managing intraocular lenses in difficult cases.
The Eye Center at UC Davis Health has two new endowed chairs focused on glaucoma, thanks to a $4 million donation from business entrepreneur Daryl Geweke.
Ophthalmologists should instruct their patients to pay attention to their eye health for the long term.
In AMD research, the experimental animals used are often young male mice. This is not optimal for the development of new treatments, as the disease most often affects the elderly – and women.
Cataract density and the fragmentation pattern the surgeon uses may influence the amount of ultrasound energy used for phacoemulsification and EPT.
Claes H. Dohlman, MD, PhD, widely considered the father of modern cornea science, is a recipient of the 2022 António Champalimaud Vision Award. The award, considered the “Nobel Prize of Vision," comes with a $1 million prize .
According to Rishi P. Singh, MD, family history and lifestyle are key in the development of geographic atrophy.
Researchers found that the rate of visual decline increased significantly in patients with age-related macular degeneration (AMD) during the COVID-19 lockdown who were followed over time.
LUNA trial will evaluate the 2x10^11 vg/eye (2E11) and a new lower 6x10^10 vg/eye (6E10) dose of Ixo-vec, with enhanced prophylactic steroid regimens in patients requiring frequent anti-VEGF injections. Interim data anticipated throughout 2023.
Heru debuts dark adaptation, the newest modality added to its wearable health and wellness platform’s vision screening line-up.
Medication is administered after LASIK and injectable prophylaxis during cataract surgery.
No one should ever have to choose between quality health care and preserving money, especially for those we love or for ourselves.
Sigma extends access to powerful no-code cloudscale data analytics for industry-compliant data cloud so healthcare professionals and researchers can find faster answers to critical questions.
Nanoscope Therapeutics’ Phase 2 STARLIGHT open-label trial enrolled 6 subjects with advanced vision loss due to a clinical or genetic diagnosis of Stargardt disease.